Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer : long-term results of phase II OIGIT-01 Trial
Authors:ID Golo, Danijela (Author)
ID But-Hadžić, Jasna (Author)
ID Anderluh, Franc (Author)
ID Brecelj, Erik (Author)
ID Edhemović, Ibrahim (Author)
ID Jeromen, Ana (Author)
ID Omejc, Mirko (Author)
ID Oblak, Irena (Author)
ID Šečerov Ermenc, Ajra (Author)
ID Velenik, Vaneja (Author)
Files:URL URL - Source URL, visit https://content.sciendo.com/view/journals/raon/52/3/article-p267.xml
 
.pdf PDF - Presentation file, download (1,27 MB)
MD5: 9F846E2FCD30FE029C03B1EDDC17A28B
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:The purpose of the study was to improve treatment efficacy for locally advanced rectal cancer (LARC) by shifting half of adjuvant chemotherapy preoperatively to one induction and two consolidation cycles. Patients and methods Between October 2011 and April 2013, 66 patients with LARC were treated with one induction chemotherapy cycle followed by chemoradiotherapy (CRT), two consolidation cycles, surgery and three adjuvant capecitabine cycles. Radiation doses were 50.4 Gy for T2-3 and 54 Gy for T4 tumours in 1.8 Gy daily fraction. The doses of concomitant and neo/adjuvant capecitabine were 825 mg/m2/12h and 1250mg/m2/12h, respectively. The primary endpoint was pathologic complete response (pCR). Results Forty-three (65.1%) patients were treated according to protocol. The compliance rates for induction, consolidation, and adjuvant chemotherapy were 98.5%, 93.8% and 87.3%, respectively. CRT was completed by 65/66 patients, with G % 3 non-hematologic toxicity at 13.6%. The rate of pCR (17.5%) was not increased, but N and the total-down staging rates were 77.7% and 79.3%, respectively. In a median follow-up of 55 months, we recorded one local relapse (LR) (1.6%). The 5-year disease-free survival (DFS) and overall survival (OS) rates were 64.0% (95% CI 63.89%64.11) and 69.5% (95% CI 69.39%69.61), respectively. Conclusions In LARC preoperative treatment intensification with capecitabine before and after radiotherapy is well tolerated, with a high compliance rate and acceptable toxicity. Though it does not improve the local effect, it achieves a high LR rate, DFS, and OS.
Keywords:rectal cancer, neoadjuvant chemotherapy, preoperative chemoradiotherapy
Publication status:Published
Publication version:Version of Record
Publication date:01.09.2018
Publisher:Association of Radiology and Oncology
Year of publishing:2018
Number of pages:str. 267-274, III
Numbering:Vol. 52, no. 3
Source:Ljubljana
PID:20.500.12556/DiRROS-19082 New window
UDC:616.3
ISSN on article:1318-2099
COBISS.SI-ID:3025275 New window
Copyright:by Authors
Publication date in DiRROS:11.06.2024
Views:39
Downloads:22
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Secondary language

Language:Slovenian
Keywords:rak danke, neoadjuvantna kemoterapija, predoperativna kemoradioterapija


Back